Kairos Pharma: D. Boral Capital maintains Buy, PT raised to $9.

Kairos Pharma: D. Boral Capital maintains Buy, PT raised to $9.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, recently presented positive interim efficacy data from its Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the annual European Society Medical Oncologists meeting in Berlin, Germany. The company's lead candidate, ENV-105, is a first-in-class CD105 antagonist that has shown clinical benefit when combined with hormone therapy in 86% of treated patients.

The trial demonstrated that all responders remained progression-free for at least four months, with half remaining progression-free beyond one year. Notably, seven out of nine evaluable patients experienced a reduction in PSA levels from baseline. Dr. Neil Bhowmick, CSO of Kairos Pharma, stated that the positive safety profile and initial clinical benefit validate the comprehensive mechanism of action studies that preceded this clinical study.

The 13.7 median progression-free survival (PFS) achieved by imaging with the ENV-105 and apalutamide combination suggests an improvement over current alternatives of chemotherapy and radioligand therapy, in terms of disease control as well as tolerability. Kairos Pharma seeks to provide a safe and effective therapy with ENV-105 for the over 3 million men with hormone-resistant prostate cancer worldwide.

In response to these positive results, D. Boral Capital has maintained its "Buy" rating on Kairos Pharma and raised its price target to $9. The firm's analysts highlighted the potential of ENV-105 to address significant unmet medical needs and improve patient outcomes.